Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 18, 2026, STAAR Surgical Company (the “ Company”) held its 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s shareholders approved Amendment No. 2 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “ Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 3,900,000 shares (the “ Plan Amendment”). Descriptions of the Plan and the Plan Amendment can be found in“ Proposal No. 2: Approval of Amendment No. 2 to Amended and Restated Omnibus Equity Incentive Plan” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 4, 2026 (the “2026 Proxy Statement”). Such descriptions are incorporated herein by reference from the 2026 Proxy Statement and are qualified in their entirety by reference to the Plan, a copy of which is filed as Exhibit 10.1 to this current report, Amendment No. 1 to the Plan, a copy of which is filed as Exhibit 10.2 to this current report, and the Plan Amendment, a copy of which is filed as Exhibit 10.3 to this current report.

Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2026 Annual Meeting, the Company’s shareholders voted upon four proposals (the “ Proposals”), as described in the 2026 Proxy Statement. The final results for the votes cast with respect to the Proposals are set forth below. As of April 20, 2026, the record date for the 2026 Annual Meeting, there were 49,788,295 outstanding shares of the Company’s common stock. At the 2026 Annual Meeting, a quorum of 43,680,435 shares of the Company’s common stock were represented in person or by proxy. Proposal 1: To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified: Number of Shares For Withheld Broker Non-Votes Neal C. Bradsher 40,776,719 497,602 2,406,114 Arthur C. Butcher 40,565,567 708,754 2,406,114 Wei Jiang 41,098,173 176,148 2,406,114 Richard T. LeBuhn 41,170,957 103,364 2,406,114 Louis E. Silverman 40,487,195 787,126 2,406,114 Christopher M. Wang 40,941,468 332,853 2,406,114 Lilian Y. Zhou 40,488,276 786,045 2,406,114 Proposal 2: To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares: Number of Shares For Against Abstain Broker Non-Votes 40,231,475 974,989 67,857 2,406,114 Proposal 3: To ratify the appointment of BDO USA, P. C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027: Number of Shares For Against Abstain Broker Non-Votes 43,433,234 237,151 10,050 0 Proposal 4: To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes 39,737,385 1,454,186 82,750 2,406,114

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2024). 10.2 Amendment No. 1 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2024). ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 10.3* Amendment No. 2 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). ________ * Filed herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company June 22, 2026 By: /s/ Deborah Andrews Deborah Andrews Interim Co-Chief Executive Officer